var data={"title":"Equine serum heptavalent botulism antitoxin (United States: Availability limited to CDC distribution from strategic national stockpile in consultation with local health department): Pediatric drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Equine serum heptavalent botulism antitoxin (United States:&nbsp;Availability limited to&nbsp;CDC&nbsp;distribution from strategic national stockpile in consultation with local health department): Pediatric drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/542470?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=equine-serum-heptavalent-botulism-antitoxin-united-states-availability-limited-to-cdc-distribution-from-strategic-national-stockpile-in-consultation-with-local-health-department-drug-information\" class=\"drug drug_general\">see &quot;Equine serum heptavalent botulism antitoxin (United States:&nbsp;Availability limited to&nbsp;CDC&nbsp;distribution from strategic national stockpile in consultation with local health department): Drug information&quot;</a> and <a href=\"topic.htm?path=equine-serum-heptavalent-botulism-antitoxin-united-states-availability-limited-to-cdc-distribution-from-strategic-national-stockpile-in-consultation-with-local-health-department-patient-drug-information\" class=\"drug drug_patient\">see &quot;Equine serum heptavalent botulism antitoxin (United States:&nbsp;Availability limited to&nbsp;CDC&nbsp;distribution from strategic national stockpile in consultation with local health department): Patient drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F25341098\" class=\"list_set htclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Therapeutic Category</span>\n    <ul>\n      <li>\n        <span class=\"list-set-name\">Antitoxin</span></li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F26419178\" class=\"block don drugH1Div\"><span class=\"drugH1\">Dosing: Neonatal</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Note:</b> Consider a pretreatment skin sensitivity test in patients at risk for severe hypersensitivity reaction. The total volume contained in one vial (regardless of vial size) will differ by lot number (~10 to 22 mL per vial). In order to calculate partial vial doses (eg, neonatal dosing), withdrawal of the entire contents of the vial to determine the total volume in the vial is required. </p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Skin sensitivity test:</b> Intradermal: 0.02 mL of a 1:1,000 dilution in NS administered intradermally on the volar surface of the forearm; if the test is negative, repeat the test using a 1:100 dilution. Perform concurrent positive (histamine) and negative (saline) control tests. A positive reaction is a wheal with surrounding erythema &ge;3 mm larger than the negative control test (saline) when read at 15 to 20 minutes. The histamine control test must be positive for valid interpretation. A negative reaction does not rule out the possibility of an immediate or delayed reaction with treatment.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Botulism, treatment:</b> IV: 10% of the adult dose (one vial), regardless of body weight </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F25341104\" class=\"block dos drugH1Div\"><span class=\"drugH1\">Dosing: Pediatric</span><p>(For additional information <a href=\"topic.htm?path=equine-serum-heptavalent-botulism-antitoxin-united-states-availability-limited-to-cdc-distribution-from-strategic-national-stockpile-in-consultation-with-local-health-department-drug-information\" class=\"drug drug_general\">see &quot;Equine serum heptavalent botulism antitoxin (United States:&nbsp;Availability limited to&nbsp;CDC&nbsp;distribution from strategic national stockpile in consultation with local health department): Drug information&quot;</a>)</p>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Note:</b> Consider a pretreatment skin sensitivity test in patients at risk for severe hypersensitivity reactions. The total volume contained in one vial (regardless of vial size) will differ by lot number (~10 to 22 mL per vial). In order to calculate partial vial doses (eg, pediatric dosing), withdrawal of the entire contents of the vial to determine the total volume in the vial is required. </p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pediatric:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Skin sensitivity test:</b> Infants, Children, and Adolescents: Intradermal: 0.02 mL of a 1:1,000 dilution in NS administered intradermally on the volar surface of the forearm; if the test is negative, repeat the test using a 1:100 dilution. Perform concurrent positive (histamine) and negative (saline) control tests. A positive reaction is a wheal with surrounding erythema &ge;3 mm larger than the negative control test (saline) when read at 15 to 20 minutes. The histamine control test must be positive for valid interpretation. A negative reaction does not rule out the possibility of an immediate or delayed reaction with treatment.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Botulism, treatment:</b> IV:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Infants &lt;1 year: 10% of the adult dose (one vial), regardless of body weight </p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Children &ge;1 year and Adolescents &lt;17 years: 20% to 100% of the adult dose dependent upon patient weight; minimum dose: 20% of one vial; maximum dose: One vial</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">The percentage of the adult dose to be administered is based on patient weight according to the following Salisbury Rule equations: </p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">&le;30 kg: Percentage (%) of Adult Dose to be Administered = Weight (kg) x 2 </p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">&gt;30 kg: Percentage (%) of Adult Dose to be Administered = Weight (kg) + 30 </p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">The following doses are recommended using the above equations: </p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">10 to 14 kg: 20% of one vial </p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">15 to 19 kg: 30% of one vial </p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">20 to 24 kg: 40% of one vial </p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">25 to 29 kg: 50% of one vial </p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">30 to 34 kg: 60% of one vial </p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">35 to 39 kg: 65% of one vial </p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">40 to 44 kg: 70% of one vial </p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">45 to 49 kg: 75% of one vial </p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">50 to 54 kg: 80% of one vial </p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">&ge;55 kg: One vial </p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Adolescents &ge;17 years: One vial </p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Adult:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Skin sensitivity test:</b> Intradermal: 0.02 mL of a 1:1,000 dilution given intradermally on the volar surface of the forearm; if the test is negative, repeat the test using a 1:100 dilution. Perform concurrent positive (histamine) and negative (saline) control tests. A positive reaction is a wheal with surrounding erythema &ge;3 mm larger than the negative control test (saline) when read at 15 to 20 minutes. The histamine control test must be positive for valid interpretation. A negative reaction does not rule out the possibility of an immediate or delayed reaction with treatment.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Botulism, treatment:</b> IV: One vial</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosing adjustment in renal impairment:</b> There are no dosage adjustment provided in manufacturer's labeling (has not been studied). </p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosing adjustment in hepatic impairment:</b> There are no dosage adjustment provided in manufacturer's labeling (has not been studied). </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F51083166\" class=\"block dorp drugH1Div\"><span class=\"drugH1\">Dosing: Renal Impairment (Pediatric)</span>\n    <p style=\"text-indent:0em;display:inline\">There are no dosage adjustment provided in manufacturer's labeling (has not been studied).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F51083167\" class=\"block dohp drugH1Div\"><span class=\"drugH1\">Dosing: Hepatic Impairment (Pediatric)</span>\n    <p style=\"text-indent:0em;display:inline\">There are no dosage adjustment provided in manufacturer's labeling (has not been studied).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16608428\" class=\"block doa drugH1Div\"><span class=\"drugH1\">Dosing: Adult</span><p>(For additional information <a href=\"topic.htm?path=equine-serum-heptavalent-botulism-antitoxin-united-states-availability-limited-to-cdc-distribution-from-strategic-national-stockpile-in-consultation-with-local-health-department-drug-information\" class=\"drug drug_general\">see &quot;Equine serum heptavalent botulism antitoxin (United States:&nbsp;Availability limited to&nbsp;CDC&nbsp;distribution from strategic national stockpile in consultation with local health department): Drug information&quot;</a>)</p>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Botulism:</b> Treatment: IV: One vial; <b>Note:</b> The total volume contained in one vial (regardless of vial size) will differ by lot number (~10 to 22 mL per vial).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F50990181\" class=\"block dora drugH1Div\"><span class=\"drugH1\">Dosing: Renal Impairment (Adult)</span>\n    <p style=\"text-indent:0em;display:inline\">There are no dosage adjustments provided in the manufacturer's labeling (has not been studied).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F50987547\" class=\"block doha drugH1Div\"><span class=\"drugH1\">Dosing: Hepatic Impairment (Adult)</span>\n    <p style=\"text-indent:0em;display:inline\">There are no dosage adjustments provided in the manufacturer's labeling (has not been studied).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16610641\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Injection, solution [preservative free]: Each vial contains no less than serotype A antitoxin 4500 units, serotype B antitoxin 3300 units, serotype C antitoxin 3000 units, serotype D antitoxin 600 units, serotype E antitoxin 5100 units, serotype F antitoxin 3000 units, and serotype G antitoxin 600 units (20 mL, 50 mL)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16608351\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Availability (US)</span>\n    <p style=\"text-indent:0em;display:inline\">Yes</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16608350\" class=\"block accres drugH1Div\"><span class=\"drugH1\">Prescribing and Access Restrictions</span>\n    <p style=\"text-indent:0em;display:inline\">Heptavalent botulism antitoxin is not available for general public use. All supplies are currently owned by the federal government for inclusion in the Strategic National Stockpile and are distributed by the Centers for Disease Control and Prevention (CDC). Clinicians who suspect botulism in a patient are instructed to call their state health department&rsquo;s emergency 24-hour telephone number; the state health department will contact the CDC to request release of botulism antitoxin, if indicated. State health departments can contact the CDC at their 24-hour telephone number at (770) 488-7100. Additional information from the CDC is available at <a target=\"_blank\" href=\"https://www.cdc.gov/laboratory/drugservice/formulary.html&amp;token=8fUMx+fB4trlY8x/Mo8Y9Ddj5kItZ1H7qlW/e3GJptY28xGubTU0DXWzUi5nl8+CwNhzfAcY95p7Mq5fGdd6Fg==&amp;TOPIC_ID=98478\" target=\"_blank\">https://www.cdc.gov/laboratory/drugservice/formulary.html</a>.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F25341105\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Intradermal: Skin sensitivity testing: Administer enough diluted antitoxin intradermally on the volar surface of the forearm to raise a small wheal; perform concurrent positive (histamine) and negative (saline) control tests. </p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">IV: Botulism treatment: Consider a pretreatment skin sensitivity test in patients at risk for severe hypersensitivity reactions. Treatment doses should be diluted to a 1:10 dilution prior to administration. Use of an in-line filter is optional. A slower infusion rate should be used during the first 30 minutes of treatment; if tolerated, may increase rate every 30 minutes up to the maximum infusion rate for the remainder of the infusion. Monitor vital signs throughout the infusion. Initiate and increase the infusion rate as follows: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Pediatric: </p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Infants &lt;1 year: Initial: 0.01 mL/kg/minute; may increase the rate by 0.01 mL/kg/minute every 30 minutes to a maximum infusion rate of 0.03 mL/kg/minute </p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Children &ge;1 year and Adolescents &lt;17 years: Initial: 0.01 mL/kg/minute (maximum initial rate: 0.5 mL/minute); may increase the rate by 0.01 mL/kg/minute every 30 minutes to a maximum infusion rate of 0.03 mL/kg/minute (maximum rate: 2 mL/minute) </p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Adolescents &ge;17 years: Initial: 0.5 mL/minutes; may double the infusion rate, if tolerated, every 30 minutes to a maximum infusion rate of 2 mL/minute </p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Adult: Initial: 0.5 mL/minutes; may double the infusion rate, if tolerated, every 30 minutes to a maximum infusion rate of 2 mL/minute </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16608384\" class=\"block sts drugH1Div\"><span class=\"drugH1\">Storage/Stability</span>\n    <p style=\"text-indent:0em;display:inline\">Store intact vials frozen at &le;-15&deg;C (&le;5&deg;F) until use; once thawed, may be stored at 2&deg;C to 8&deg;C (36&deg;F to 48&deg;F) for up to 36 months or until 48 months from date of manufacture (whichever comes first).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F25341099\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:0em;display:inline\">Treatment of symptomatic botulism following documented or suspected exposure to any of the seven serotypes of botulinum neurotoxin serotypes (serotypes A, B, C, D, E, F, or G) (FDA approved in pediatric patients [age not specified] and adults)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16608380\" class=\"block arm drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:0em;margin-right:2em;\">Cardiovascular: Edema</p>\n    <p style=\"text-indent:0em;margin-right:2em;\">Central nervous system: Chills, headache</p>\n    <p style=\"text-indent:0em;margin-right:2em;\">Dermatologic: Pruritus, skin rash, urticaria</p>\n    <p style=\"text-indent:0em;margin-right:2em;\">Gastrointestinal: Nausea, sore throat</p>\n    <p style=\"text-indent:0em;margin-right:2em;\">Miscellaneous: Fever</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Rare but important or life-threatening: Agitation, anaphylactic shock, anaphylactoid reaction, anaphylaxis, angioedema, anxiety, asystole, bradycardia, bronchospasm, chest discomfort, erythema, hyperhidrosis, hypersensitivity reaction, hypotension, increased blood pressure, infusion related reaction, jitteriness, leukocytosis, serum sickness, tachycardia, urinary retention, vomiting</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16608359\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:0em;display:inline\">There are no contraindications listed in the manufacturer&rsquo;s labeling.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16608362\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Delayed allergic reaction: Delayed allergic reaction or serum sickness (eg, arthralgia, fever, lymphadenopathy, myalgia, urticarial or maculopapular rash) may occur 10 to 21 days after administration. Monitor all patients for delayed allergic reactions and administer appropriate medical care as needed.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hypersensitivity: Severe hypersensitivity reactions, including anaphylaxis and anaphylactoid reactions, may occur. The risk is greatest in patients with a history of hypersensitivity to horses or equine blood products, asthma, or hay fever; initiate treatment at the lowest achievable infusion rate (&lt;0.01 mL/minute) is recommended. Monitor all patients for acute allergic reactions during and following the infusion; discontinue antitoxin administration in patients who develop a hypersensitivity reaction. Immediate treatment (including epinephrine 1 mg/mL) should be available.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Infusion reactions: Infusion reactions (eg, arthralgia, chills, fatigue, fever, headache, myalgia, nausea, vasovagal reactions, vomiting) may occur; monitor all patients for infusion reactions during and following the infusion. In patients who develop an infusion reaction, decrease the infusion rate and treat symptomatically; if symptoms worsen, discontinue the infusion.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Dosage form specific issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Maltose: May contain maltose which may falsely elevate glucose readings</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Polysorbate 80: Some dosage forms may contain polysorbate 80 (also known as Tweens). Hypersensitivity reactions, usually a delayed reaction, have been reported following exposure to pharmaceutical products containing polysorbate 80 in certain individuals (Isaksson 2002; Lucente 2000; Shelley 1995). Thrombocytopenia, ascites, pulmonary deterioration, and renal and hepatic failure have been reported in premature neonates after receiving parenteral products containing polysorbate 80 (Alade 1986; CDC 1984). See manufacturer&rsquo;s labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Vial contents: Each vial contains a minimum antitoxin potency. The total volume contained in one vial (regardless of vial size) will differ by lot number (~10 to 22 mL per vial); therefore, withdrawal of the entire vial contents will be required to calculate the dose.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Appropriate use: Botulism: Antitoxin is most effective if administered as early as possible (ideally within 12 to 48 hours) after the onset of neurologic symptoms (Fagan 2011a). Antitoxin does not reverse existing paralysis, but it arrests its progression.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Disease transmission: Product of equine (horse) plasma; may potentially contain infectious agents (eg, viruses) which could transmit disease. Infections thought to be transmitted by this product should be reported to the manufacturer at 1-800-768-2304.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F26419177\" class=\"block add-pediatric-warn-info drugH1Div\"><span class=\"drugH1\">Warnings: Additional Pediatric Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">The safety and efficacy information in pediatric patients is derived from animal model studies. Dosing in pediatric patients is based on the Salisbury Rule. Limited pediatric data safety data available; a CDC expanded access clinical study including 15 pediatric subjects (age range:  10 days to 17 years) reported adverse reactions in two patients; one subject experienced tachycardia, bradycardia, and asystole during infusion; pyrexia was reported in the other patient.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F17917883\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F17917881\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=98478&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:0em;display:inline\">There are no known significant interactions.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16608356\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Animal reproduction studies have not been conducted. Based on limited information with the use of the previous equine products (BAT-AB; BAT-E), there is no indication that treatment of pregnant patients with botulism should differ from standard therapy (Arnon 2001). In general, medications used as antidotes should take into consideration the health and prognosis of the mother; antidotes should be administered to pregnant women if there is a clear indication for use and should not be withheld because of fears of teratogenicity (Bailey 2003).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F25341106\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">Monitor vital signs and for the presence of infusion-related reactions and acute hypersensitivity reactions during and immediately following infusion; monitor for delayed allergic reactions for 10 to 21 days after administration. </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16608388\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Contains toxin-specific F(ab&rsquo;)<sub>2</sub> and F(ab&rsquo;)<sub>2</sub>-related antibody fragments which bind and neutralize free botulinum neurotoxin A, B, C, D, E, F, and G. As a result, the neurotoxins are prevented from interacting with the cholinergic nerve ending and internalizing into target cells, thereby minimizing nerve damage and severity of the disease. Clinicians should note that botulism antitoxin does not reverse preexisting toxic manifestations.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16608392\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics (Adult data unless noted)</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Distribution: V<sub>d</sub>:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Antitoxin serotype A: 3.6 L</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Antitoxin serotype B: 9.6 L</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Antitoxin serotype C: 6.1 L</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Antitoxin serotype D: 1.5 L</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Antitoxin serotype E: 14.2 L</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Antitoxin serotype F: 3.4 L</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Antitoxin serotype G: 2.4 L</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Half-life elimination:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Antitoxin serotype A: 8.6 hours</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Antitoxin serotype B: 34.2 hours</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Antitoxin serotype C: 29.6 hours</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Antitoxin serotype D: 7.5 hours</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Antitoxin serotype E: 7.8 hours</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Antitoxin serotype F: 14.1 hours</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Antitoxin serotype G: 11.7 hours</p></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Alade SL, Brown RE, Paquet A. Polysorbate 80 and E-Ferol toxicity. Pediatrics. 1986;77(4):593-597.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Arnon SS, Schechter R, Inglesby TV, et al, &quot;Botulinum Toxin as a Biological Weapon: Medical and Public Health Management,&quot; <i>JAMA</i>, 2001, 285(8):1059-70.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/equine-serum-heptavalent-botulism-antitoxin-united-states-availability-limited-to-cdc-distribution-from-strategic-national-stockpile-in-consultation-with-local-health-department-pediatric-drug-information/abstract-text/11209178/pubmed\" target=\"_blank\" id=\"11209178\">11209178</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Bailey B, &quot;Are There Teratogenic Risks Associated With Antidotes Used in the Acute Management of Poisoned Pregnant Women?&quot; <i>Birth Defects Res A Clin Mol Teratol</i>, 2003, 67(2):133-40.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/equine-serum-heptavalent-botulism-antitoxin-united-states-availability-limited-to-cdc-distribution-from-strategic-national-stockpile-in-consultation-with-local-health-department-pediatric-drug-information/abstract-text/12769509/pubmed\" target=\"_blank\" id=\"12769509\">12769509</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    BAT (botulism antitoxin heptavalent) [prescribing information]. Winnipeg, Manitoba, Canada: Cangene Corporation; March 2013.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Centers for Disease Control and Prevention (CDC), &quot;Investigational Heptavalent Botulinum Antitoxin (HBAT) to Replace Licensed Botulinum Antitoxin AB and Investigational Botulinum Antitoxin E,&quot; <i>MMWR Morb Mortal Wkly Rep</i>, 2010, 59(10):299.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/equine-serum-heptavalent-botulism-antitoxin-united-states-availability-limited-to-cdc-distribution-from-strategic-national-stockpile-in-consultation-with-local-health-department-pediatric-drug-information/abstract-text/20300057/pubmed\" target=\"_blank\" id=\"20300057\">20300057</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Centers for Disease Control (CDC). Unusual syndrome with fatalities among premature infants: association with a new intravenous vitamin E product. MMWR Morb Mortal Wkly Rep. 1984;33(14):198-199 <a href=\"http://www.cdc.gov/mmwr/preview/mmwrhtml/00000319.htm\" target=\"_blank\">http://www.cdc.gov/mmwr/preview/mmwrhtml/00000319.htm</a></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Fagan RP, McLaughlin JB, Castrodale LJ, et al, &quot;Endemic Foodborne Botulism Among Alaska Native Persons--Alaska, 1947-2007,&quot; <i>Clin Infect Dis</i>, 2011a, 52(5):585-92.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/equine-serum-heptavalent-botulism-antitoxin-united-states-availability-limited-to-cdc-distribution-from-strategic-national-stockpile-in-consultation-with-local-health-department-pediatric-drug-information/abstract-text/21292663/pubmed\" target=\"_blank\" id=\"21292663\">21292663</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Fagan RP, Neil KP, Sasich R, et al, &quot;Initial Recovery and Rebound of Type F Intestinal Colonization Botulism After Administration of Investigational Heptavalent Botulinum Antitoxin,&quot; <i>Clin Infect Dis</i>, 2011b, 53(9):e125-8.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/equine-serum-heptavalent-botulism-antitoxin-united-states-availability-limited-to-cdc-distribution-from-strategic-national-stockpile-in-consultation-with-local-health-department-pediatric-drug-information/abstract-text/21896700/pubmed\" target=\"_blank\" id=\"21896700\">21896700</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Hill, SE, Iqbal, R., Cadiz, CL, et al, &quot;Foodborne Botulism Treated With Heptavalent Botulism Antitoxin,&quot; <i>Ann Pharmacother</i>, 2013, 47(2):e12.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/equine-serum-heptavalent-botulism-antitoxin-united-states-availability-limited-to-cdc-distribution-from-strategic-national-stockpile-in-consultation-with-local-health-department-pediatric-drug-information/abstract-text/23362041/pubmed\" target=\"_blank\" id=\"23362041\">23362041</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n     Isaksson M, Jansson L. Contact allergy to Tween 80 in an inhalation suspension. Contact Dermatitis. 2002;47:313.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lucente P, Iorizzo M, Pazzaglia M. Contact sensitivity to Tween 80 in a child. Contact Dermatitis. 2000;43:172.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Shelley WB, Talanin N, Shelley ED. Polysorbate 80 hypersensitivity. Lancet. 1995;345(8980):1312-1313.</div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 98478 Version 23.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Therapeutic Category\" href=\"#F25341098\" class=\"outlineLink\">Therapeutic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Neonatal\" href=\"#F26419178\" class=\"outlineLink\">Dosing: Neonatal</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Pediatric\" href=\"#F25341104\" class=\"outlineLink\">Dosing: Pediatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Renal Impairment (Pediatric)\" href=\"#F51083166\" class=\"outlineLink\">Dosing: Renal Impairment (Pediatric)</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Hepatic Impairment (Pediatric)\" href=\"#F51083167\" class=\"outlineLink\">Dosing: Hepatic Impairment (Pediatric)</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adult\" href=\"#F16608428\" class=\"outlineLink\">Dosing: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Renal Impairment (Adult)\" href=\"#F50990181\" class=\"outlineLink\">Dosing: Renal Impairment (Adult)</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Hepatic Impairment (Adult)\" href=\"#F50987547\" class=\"outlineLink\">Dosing: Hepatic Impairment (Adult)</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F16610641\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Availability (US)\" href=\"#F16608351\" class=\"outlineLink\">Generic Availability (US)</a></li><li class=\"plainItem\"><a sectionName=\"Prescribing and Access Restrictions\" href=\"#F16608350\" class=\"outlineLink\">Prescribing and Access Restrictions</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F25341105\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Storage/Stability\" href=\"#F16608384\" class=\"outlineLink\">Storage/Stability</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F25341099\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F16608380\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F16608359\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F16608362\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Warnings: Additional Pediatric Considerations\" href=\"#F26419177\" class=\"outlineLink\">Warnings: Additional Pediatric Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F17917883\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F17917881\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F16608356\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F25341106\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F16608388\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics (Adult data unless noted)\" href=\"#F16608392\" class=\"outlineLink\">Pharmacodynamics/Kinetics (Adult data unless noted)</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_PED/98478|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=equine-serum-heptavalent-botulism-antitoxin-united-states-availability-limited-to-cdc-distribution-from-strategic-national-stockpile-in-consultation-with-local-health-department-drug-information\" class=\"drug drug_general\">Equine serum heptavalent botulism antitoxin (United States:&nbsp;Availability limited to&nbsp;CDC&nbsp;distribution from strategic national stockpile in consultation with local health department): Drug information</a></li><li><a href=\"topic.htm?path=equine-serum-heptavalent-botulism-antitoxin-united-states-availability-limited-to-cdc-distribution-from-strategic-national-stockpile-in-consultation-with-local-health-department-patient-drug-information\" class=\"drug drug_patient\">Equine serum heptavalent botulism antitoxin (United States:&nbsp;Availability limited to&nbsp;CDC&nbsp;distribution from strategic national stockpile in consultation with local health department): Patient drug information</a></li></ul></div></div>","javascript":null}